EA201990258A1 - ANTIBODIES TO TIM-3 - Google Patents
ANTIBODIES TO TIM-3Info
- Publication number
- EA201990258A1 EA201990258A1 EA201990258A EA201990258A EA201990258A1 EA 201990258 A1 EA201990258 A1 EA 201990258A1 EA 201990258 A EA201990258 A EA 201990258A EA 201990258 A EA201990258 A EA 201990258A EA 201990258 A1 EA201990258 A1 EA 201990258A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tim
- antibodies
- mucin
- monotherapy
- chemotherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Данное изобретение относится к антителам, которые связывают человеческий T-клеточный белок 3, содержащий домены иммуноглобулина и муцина (Tim-3), и могут быть пригодны для лечения солидных и гематологических опухолей как в качестве монотерапии, так и в комбинации с химиотерапией и ионизирующим излучением.This invention relates to antibodies that bind a human T-cell protein 3 containing immunoglobulin and mucin (Tim-3) domains, and may be suitable for the treatment of solid and hematological tumors both as monotherapy and in combination with chemotherapy and ionizing radiation .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762469753P | 2017-03-10 | 2017-03-10 | |
PCT/US2017/047261 WO2018039020A1 (en) | 2016-08-25 | 2017-08-17 | Anti-tim-3 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201990258A1 true EA201990258A1 (en) | 2019-07-31 |
Family
ID=67399635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201990258A EA201990258A1 (en) | 2017-03-10 | 2017-08-17 | ANTIBODIES TO TIM-3 |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201990258A1 (en) |
-
2017
- 2017-08-17 EA EA201990258A patent/EA201990258A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991156A1 (en) | ANTIBODIES TO Tim-3 FOR COMBINATION WITH ANTIBODIES TO PD-1 | |
JOP20190013A1 (en) | Anti-tim-3 antibodies | |
EA201890278A1 (en) | ANTIBODIES TO PD-L1 | |
EA202090204A1 (en) | ANTI-CD137 ANTIBODIES | |
EA201792221A1 (en) | ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION | |
MY191649A (en) | Antibodies to tigit | |
PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
TN2019000294A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
MX2022004072A (en) | Factor xi antibodies and methods of use. | |
BR112019024654A2 (en) | binding protein nkg2d, cd16 and ror1 or ror2 | |
EA202092306A1 (en) | ANTI-CD24 COMPOSITIONS AND THEIR APPLICATIONS | |
EA201792300A1 (en) | COMBINATIONS OF IMMUNOCONGAGED TO CD37 AND ANTIBODIES TO CD20 | |
EA202192796A1 (en) | TIGIT AND PD-1/TIGIT BINDING MOLECULES | |
EA201791691A1 (en) | SINGLE-DOMAIN ANTIBODIES DIRECTED TO CD1d | |
EA202092085A1 (en) | THERAPEUTIC ANTIBODIES AGAINST sPLA2-GIB AND THEIR APPLICATION | |
EA201992145A1 (en) | ANTI-PD-L1-ANTI-TIM-3 SPECIFIC ANTIBODIES | |
EA202092262A1 (en) | ANTIBODIES AGAINST CD137 FOR COMBINATION WITH ANTIBODIES AGAINST PD-1 | |
EA202092265A1 (en) | ANTIBODIES AGAINST CD137 FOR COMBINATION WITH ANTIBODIES AGAINST PD-L1 | |
EA201990258A1 (en) | ANTIBODIES TO TIM-3 | |
EA202092279A1 (en) | ANTIBODIES TO MICA AND / OR MICB AND THEIR APPLICATION |